Viewing StudyNCT00464178



Ignite Creation Date: 2024-05-05 @ 5:28 PM
Last Modification Date: 2024-10-26 @ 9:32 AM
Study NCT ID: NCT00464178
Status: TERMINATED
Last Update Posted: 2022-07-20
First Post: 2007-04-19

Brief Title: A Phase II Study of Bevacizumab and Bortezomib in Patients With RelapsedRefractory Multiple Myeloma
Sponsor: Hackensack Meridian Health
Organization: Hackensack Meridian Health

Conditions & Keywords Data

Conditions:
Name
Multiple Myeloma
Keywords:
Name View
myeloma protein Wis human View
multiple myeloma View
myeloma View
relapsed myeloma View
refractory myeloma View
relapsed refractory myeloma View
relapsed refractory multiple myeloma View
refractory multiple myeloma View
relapsed multiple myeloma View
B lymphoid malignancies View
Myeloma Plasma-Cell View
Myeloma Proteins View
hnRNP A1 View
myeloma helix-destabilizing protein mouse View
IgC3kappa Jir protein human View
gamma 3 myeloma protein Jir human View
M-proteins Myeloma View
M315 myeloma protein mouse View
myeloma protein M 315 mouse View
McPC603 antibody View
myeloma protein McPC603 antibody View
multiple myeloma M-proteins View
M protein multiple myeloma View
myeloma cell activator View
myeloma immunoglobulins View
myeloma immunoglobulin M603 View
myeloma immunoglobulin S15 View
myeloma protein A48 mouse View
A48 myeloma protein mouse View
ABPC48 myeloma protein mouse View
myeloma protein A 48 mouse View
myeloma protein Dob View
myeloma protein M 467 View
myeloma protein M467 View
myeloma protein MOPC 141 mouse View
MOPC141 myeloma protein mouse View
myeloma protein MOPC 173 View
myeloma protein Rou View
IgA2 myeloma protein Rou View
myeloma protein TEPC15 View
myeloma protein T15 View
myeloma protein TEPC 15 View
myeloma protein W3129 View
myeloma protein WIE View
myeloma-associated membrane antigen KMA View
myeloma antigen KMA View
MYEOV protein human View
protein 460 View
myeloma protein MOPC 460 View
TRAPPC1 protein human View
multiple myeloma protein 2 human View
Wis heavy-chain disease protein human View